Clinical Application Value of Circulating Cell-free DNA in Hepatocellular Carcinoma
Hepatocellular carcinoma (HCC) is one of the most common cancers worldwide and a leading cause of cancer-related deaths. Due to late diagnosis, early intrahepatic metastasis and nonresponse to systemic treatments, surgical resection and/or biopsy specimens remain the gold standard for disease stagin...
Main Authors: | , , , , , , , , , , , |
---|---|
Format: | Article |
Language: | English |
Published: |
Frontiers Media S.A.
2021-09-01
|
Series: | Frontiers in Molecular Biosciences |
Subjects: | |
Online Access: | https://www.frontiersin.org/articles/10.3389/fmolb.2021.736330/full |
id |
doaj-f0a0502ec59242ada594998077999bf3 |
---|---|
record_format |
Article |
collection |
DOAJ |
language |
English |
format |
Article |
sources |
DOAJ |
author |
Yuyuan Zhang Yuyuan Zhang Yuyuan Zhang Zaoqu Liu Zaoqu Liu Zaoqu Liu Kun Ji Kun Ji Kun Ji Xin Li Xin Li Xin Li Caihong Wang Zhigang Ren Yang Liu Xinju Chen Xinwei Han Xinwei Han Xinwei Han Lingfang Meng Lifeng Li Lifeng Li Zhen Li Zhen Li Zhen Li |
spellingShingle |
Yuyuan Zhang Yuyuan Zhang Yuyuan Zhang Zaoqu Liu Zaoqu Liu Zaoqu Liu Kun Ji Kun Ji Kun Ji Xin Li Xin Li Xin Li Caihong Wang Zhigang Ren Yang Liu Xinju Chen Xinwei Han Xinwei Han Xinwei Han Lingfang Meng Lifeng Li Lifeng Li Zhen Li Zhen Li Zhen Li Clinical Application Value of Circulating Cell-free DNA in Hepatocellular Carcinoma Frontiers in Molecular Biosciences cfDNA CtDNA Hepatocellular carcinoma clinical application biomarkers |
author_facet |
Yuyuan Zhang Yuyuan Zhang Yuyuan Zhang Zaoqu Liu Zaoqu Liu Zaoqu Liu Kun Ji Kun Ji Kun Ji Xin Li Xin Li Xin Li Caihong Wang Zhigang Ren Yang Liu Xinju Chen Xinwei Han Xinwei Han Xinwei Han Lingfang Meng Lifeng Li Lifeng Li Zhen Li Zhen Li Zhen Li |
author_sort |
Yuyuan Zhang |
title |
Clinical Application Value of Circulating Cell-free DNA in Hepatocellular Carcinoma |
title_short |
Clinical Application Value of Circulating Cell-free DNA in Hepatocellular Carcinoma |
title_full |
Clinical Application Value of Circulating Cell-free DNA in Hepatocellular Carcinoma |
title_fullStr |
Clinical Application Value of Circulating Cell-free DNA in Hepatocellular Carcinoma |
title_full_unstemmed |
Clinical Application Value of Circulating Cell-free DNA in Hepatocellular Carcinoma |
title_sort |
clinical application value of circulating cell-free dna in hepatocellular carcinoma |
publisher |
Frontiers Media S.A. |
series |
Frontiers in Molecular Biosciences |
issn |
2296-889X |
publishDate |
2021-09-01 |
description |
Hepatocellular carcinoma (HCC) is one of the most common cancers worldwide and a leading cause of cancer-related deaths. Due to late diagnosis, early intrahepatic metastasis and nonresponse to systemic treatments, surgical resection and/or biopsy specimens remain the gold standard for disease staging, grading and clinical decision-making. Since only a small amount of tissue was obtained in a needle biopsy, the conventional tissue biopsy is unable to represent tumor heterogeneity in HCC. For this reason, it is imperative to find a new non-invasive and easily available diagnostic tool to detect HCC at an early stage and to monitor HCC recurrence. The past decade has witnessed considerable evolution in the development of liquid biopsy technologies with the emergence of next-generation sequencing. As a liquid biopsy approach, molecular analysis of cell-free DNA (cfDNA), characterized by noninvasiveness and real-time analysis, may accurately represent the tumor burden and comprehensively reflect genetic profile of HCC. Therefore, cfDNA may be used clinically as a predictive biomarker in early diagnosis, outcome assessment, and even molecular typing. In this review, we provide an update on the recent advances made in clinical applications of cfDNA in HCC. |
topic |
cfDNA CtDNA Hepatocellular carcinoma clinical application biomarkers |
url |
https://www.frontiersin.org/articles/10.3389/fmolb.2021.736330/full |
work_keys_str_mv |
AT yuyuanzhang clinicalapplicationvalueofcirculatingcellfreednainhepatocellularcarcinoma AT yuyuanzhang clinicalapplicationvalueofcirculatingcellfreednainhepatocellularcarcinoma AT yuyuanzhang clinicalapplicationvalueofcirculatingcellfreednainhepatocellularcarcinoma AT zaoquliu clinicalapplicationvalueofcirculatingcellfreednainhepatocellularcarcinoma AT zaoquliu clinicalapplicationvalueofcirculatingcellfreednainhepatocellularcarcinoma AT zaoquliu clinicalapplicationvalueofcirculatingcellfreednainhepatocellularcarcinoma AT kunji clinicalapplicationvalueofcirculatingcellfreednainhepatocellularcarcinoma AT kunji clinicalapplicationvalueofcirculatingcellfreednainhepatocellularcarcinoma AT kunji clinicalapplicationvalueofcirculatingcellfreednainhepatocellularcarcinoma AT xinli clinicalapplicationvalueofcirculatingcellfreednainhepatocellularcarcinoma AT xinli clinicalapplicationvalueofcirculatingcellfreednainhepatocellularcarcinoma AT xinli clinicalapplicationvalueofcirculatingcellfreednainhepatocellularcarcinoma AT caihongwang clinicalapplicationvalueofcirculatingcellfreednainhepatocellularcarcinoma AT zhigangren clinicalapplicationvalueofcirculatingcellfreednainhepatocellularcarcinoma AT yangliu clinicalapplicationvalueofcirculatingcellfreednainhepatocellularcarcinoma AT xinjuchen clinicalapplicationvalueofcirculatingcellfreednainhepatocellularcarcinoma AT xinweihan clinicalapplicationvalueofcirculatingcellfreednainhepatocellularcarcinoma AT xinweihan clinicalapplicationvalueofcirculatingcellfreednainhepatocellularcarcinoma AT xinweihan clinicalapplicationvalueofcirculatingcellfreednainhepatocellularcarcinoma AT lingfangmeng clinicalapplicationvalueofcirculatingcellfreednainhepatocellularcarcinoma AT lifengli clinicalapplicationvalueofcirculatingcellfreednainhepatocellularcarcinoma AT lifengli clinicalapplicationvalueofcirculatingcellfreednainhepatocellularcarcinoma AT zhenli clinicalapplicationvalueofcirculatingcellfreednainhepatocellularcarcinoma AT zhenli clinicalapplicationvalueofcirculatingcellfreednainhepatocellularcarcinoma AT zhenli clinicalapplicationvalueofcirculatingcellfreednainhepatocellularcarcinoma |
_version_ |
1716864749308739584 |
spelling |
doaj-f0a0502ec59242ada594998077999bf32021-09-29T05:12:24ZengFrontiers Media S.A.Frontiers in Molecular Biosciences2296-889X2021-09-01810.3389/fmolb.2021.736330736330Clinical Application Value of Circulating Cell-free DNA in Hepatocellular CarcinomaYuyuan Zhang0Yuyuan Zhang1Yuyuan Zhang2Zaoqu Liu3Zaoqu Liu4Zaoqu Liu5Kun Ji6Kun Ji7Kun Ji8Xin Li9Xin Li10Xin Li11Caihong Wang12Zhigang Ren13Yang Liu14Xinju Chen15Xinwei Han16Xinwei Han17Xinwei Han18Lingfang Meng19Lifeng Li20Lifeng Li21Zhen Li22Zhen Li23Zhen Li24Department of Interventional Radiology, The First Affiliated Hospital of Zhengzhou University, Zhengzhou, ChinaInterventional Institute of Zhengzhou University, Zhengzhou, ChinaInterventional Treatment and Clinical Research Center of Henan Province, Zhengzhou, ChinaDepartment of Interventional Radiology, The First Affiliated Hospital of Zhengzhou University, Zhengzhou, ChinaInterventional Institute of Zhengzhou University, Zhengzhou, ChinaInterventional Treatment and Clinical Research Center of Henan Province, Zhengzhou, ChinaDepartment of Interventional Radiology, The First Affiliated Hospital of Zhengzhou University, Zhengzhou, ChinaInterventional Institute of Zhengzhou University, Zhengzhou, ChinaInterventional Treatment and Clinical Research Center of Henan Province, Zhengzhou, ChinaDepartment of Interventional Radiology, The First Affiliated Hospital of Zhengzhou University, Zhengzhou, ChinaInterventional Institute of Zhengzhou University, Zhengzhou, ChinaInterventional Treatment and Clinical Research Center of Henan Province, Zhengzhou, ChinaDepartment of Magnetic Resonance, The First Affiliated Hospital, Zhengzhou University, Zhengzhou, ChinaDepartment of Infections Disease, The First Affiliated Hospital, Zhengzhou University, Zhengzhou, ChinaDepartment of Radiation Oncology, The Affiliated Cancer Hospital of Zhengzhou University, Zhengzhou, ChinaFirst Ward of Spleen, Stomach, Liver and Gall, The First Affiliated Hospital of Henan University of TCM, Zhengzhou, ChinaDepartment of Interventional Radiology, The First Affiliated Hospital of Zhengzhou University, Zhengzhou, ChinaInterventional Institute of Zhengzhou University, Zhengzhou, ChinaInterventional Treatment and Clinical Research Center of Henan Province, Zhengzhou, ChinaDepartment of Ultrasound, Zhengzhou Sixth People’s Hospital, Henan Infectious Disease Hospital, Zhengzhou, ChinaInternet Medical and System Applications of National Engineering Laboratory, Zhengzhou, China0Cancer Center, The First Affiliated Hospital of Zhengzhou University, Zhengzhou, ChinaDepartment of Interventional Radiology, The First Affiliated Hospital of Zhengzhou University, Zhengzhou, ChinaInterventional Institute of Zhengzhou University, Zhengzhou, ChinaInterventional Treatment and Clinical Research Center of Henan Province, Zhengzhou, ChinaHepatocellular carcinoma (HCC) is one of the most common cancers worldwide and a leading cause of cancer-related deaths. Due to late diagnosis, early intrahepatic metastasis and nonresponse to systemic treatments, surgical resection and/or biopsy specimens remain the gold standard for disease staging, grading and clinical decision-making. Since only a small amount of tissue was obtained in a needle biopsy, the conventional tissue biopsy is unable to represent tumor heterogeneity in HCC. For this reason, it is imperative to find a new non-invasive and easily available diagnostic tool to detect HCC at an early stage and to monitor HCC recurrence. The past decade has witnessed considerable evolution in the development of liquid biopsy technologies with the emergence of next-generation sequencing. As a liquid biopsy approach, molecular analysis of cell-free DNA (cfDNA), characterized by noninvasiveness and real-time analysis, may accurately represent the tumor burden and comprehensively reflect genetic profile of HCC. Therefore, cfDNA may be used clinically as a predictive biomarker in early diagnosis, outcome assessment, and even molecular typing. In this review, we provide an update on the recent advances made in clinical applications of cfDNA in HCC.https://www.frontiersin.org/articles/10.3389/fmolb.2021.736330/fullcfDNACtDNAHepatocellular carcinomaclinical applicationbiomarkers |